The Therapeutic Goods Administration, Australia’s regulatory body, has given clearance to Pops, a digital health company dedicated to addressing chronic conditions including diabetes. Pops, which has already been commercialized in the United States, gained prominence as winners of the 2020 Zurich Innovation Championships, where start-ups are given the chance to pitch innovative ideas to address society’s most prominent challenges. Designed to solve the traditional issues of high growth and costs associated with diabetes, outcome data published by Pops reflects continued improvement in glucose management in patients using their new self-care platform, over an 18-month period. As an innovative selfcare platform, Pops has relied on the use of an AI-driven health assistant, Mina, to address these issues surrounding chronic conditions.
Read more here.